AstraZeneca confirms talks with biotech group Acerta
Pharmaceuticals giant AstraZeneca confirmed that it is exploring potential strategic options with biotech company Acerta Pharma BV.
AstraZeneca
9,990.00p
15:45 15/11/24
-2.93%
-302.00p
FTSE 100
8,060.61
15:45 15/11/24
n/a
n/a
FTSE 350
4,453.56
15:45 15/11/24
n/a
n/a
FTSE All-Share
4,411.85
15:45 15/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
-2.70%
-535.19
“There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction,” AZN said.
The statement follows a report in the Wall Street Journal last week suggesting that the London-listed company was in advanced talks to pay more than $5bn for the cancer drug developer, which is based in California and the Netherlands.